Axsome – Talk Bio

Axsome to Pursue FDA Approval for Alzheimer’s Agitation Treatment Despite Mixed Trial Results

4 months ago talkbio0Tagged Alzheimer 's disease, Approved, AXS 05, Axsome, mixed trial, United States Food and Drug Administration

Axsome Therapeutics, Alzheimer’s disease agitation, FDA approval, mixed trial data, AXS-05

Axsome Therapeutics Narcolepsy Drug AXS-12 Achieves Phase III Success, Paving Way for US FDA Filing

5 months ago talkbio0Tagged AXS-12, Axsome, Encore, File (record), Narcolepsy, NDA, Phase 3 Clinical Trials, United States Food and Drug Administration

Axsome Therapeutics, AXS-12, narcolepsy, Phase III trial, ENCORE trial, FDA filing, NDA

Axsome Therapeutics’ Small Molecule AXS-12 Successful in Phase III Narcolepsy Trial

1 year ago talkbio0Tagged AXS-12, Axsome, Cataplexy, Drowsiness, Improved, memory/, Narcolepsy, Phase 3 Clinical Trials, reboxetine, safety profile, Severities

Axsome Therapeutics, AXS-12 (reboxetine), Phase III trial, Narcolepsy, Cataplexy reduction, Improved cognition/ memory/ sleepiness severity, Safety profile